newsfilter
← Latest News
ClinicalTrials.gov·

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2) - NCT05600777

24-Hour Cough Frequency, Change from Baseline in Cough Severity Visual Analogue Scale at Week 24, Percentage of Participants With ≥ 30mm Reduction, ≥ 20mm Reduction From Baseline in Cough Severity Visual Analog Scale (VAS) at Week 24, (and 3 more...)